These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

678 related articles for article (PubMed ID: 30380773)

  • 21. Immuno-Oncology in Hepatocellular Carcinoma: 2017 Update.
    Kudo M
    Oncology; 2017; 93 Suppl 1():147-159. PubMed ID: 29258079
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Hepatocellular Carcinoma: Beyond the Border of Advanced Stage Therapy.
    Zarlashat Y; Abbas S; Ghaffar A
    Cancers (Basel); 2024 May; 16(11):. PubMed ID: 38893154
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immuno-Oncotherapeutic Approaches in Advanced Hepatocellular Carcinoma.
    Park R; Eshrat F; Al-Jumayli M; Saeed A; Saeed A
    Vaccines (Basel); 2020 Aug; 8(3):. PubMed ID: 32784389
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Emerging role of Immune Checkpoint Inhibitors in Hepatocellular Carcinoma.
    Longo V; Brunetti O; Gnoni A; Licchetta A; Delcuratolo S; Memeo R; Solimando AG; Argentiero A
    Medicina (Kaunas); 2019 Oct; 55(10):. PubMed ID: 31627433
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Clinical research progression of molecular-targeted drugs and PD-1 inhibitors for advanced hepatocellular carcinoma].
    Lai JM; Hu S; Lin H; Luo H; Luo YB
    Zhonghua Zhong Liu Za Zhi; 2019 Jun; 41(6):406-409. PubMed ID: 31216824
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Emerging agents and regimens for hepatocellular carcinoma.
    Zhu XD; Sun HC
    J Hematol Oncol; 2019 Oct; 12(1):110. PubMed ID: 31655607
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The New Immuno-Oncology-Based Therapies and Their Perspectives in Hepatocellular Carcinoma.
    Merle P
    Cancers (Basel); 2021 Jan; 13(2):. PubMed ID: 33440630
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Review article: new therapeutic interventions for advanced hepatocellular carcinoma.
    Bangaru S; Marrero JA; Singal AG
    Aliment Pharmacol Ther; 2020 Jan; 51(1):78-89. PubMed ID: 31747082
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
    Mahoney KM; Freeman GJ; McDermott DF
    Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Hepatocellular Carcinoma: Etiology and Current and Future Drugs.
    Jindal A; Thadi A; Shailubhai K
    J Clin Exp Hepatol; 2019; 9(2):221-232. PubMed ID: 31024205
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Systemic Therapy in Advanced Hepatocellular Carcinoma: Patient Selection and Key Considerations.
    Storandt MH; Mahipal A; Tella SH; Kommalapati A; Jin Z
    J Hepatocell Carcinoma; 2022; 9():1187-1200. PubMed ID: 36471742
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Systemic therapy for hepatocellular carcinoma: current status and future perspectives.
    Furuse J; Ueno M; Ikeda M
    Jpn J Clin Oncol; 2021 Aug; 51(9):1363-1371. PubMed ID: 34258616
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Systemic Therapy for Advanced Hepatocellular Carcinoma: An Update of a Rapidly Evolving Field.
    Doycheva I; Thuluvath PJ
    J Clin Exp Hepatol; 2019; 9(5):588-596. PubMed ID: 31695249
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immune Checkpoint Inhibitors for Advanced Hepatocellular Carcinoma: Monotherapies and Combined Therapies.
    Ouyang T; Kan X; Zheng C
    Front Oncol; 2022; 12():898964. PubMed ID: 35785169
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The Evolving Landscape of Checkpoint Inhibitor Combination Therapy in the Treatment of Advanced Hepatocellular Carcinoma.
    Liu L; Qin S; Zhang Y
    Target Oncol; 2021 Mar; 16(2):153-163. PubMed ID: 33528759
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical outcomes and influencing factors of PD-1/PD-L1 in hepatocellular carcinoma.
    Wang J; Li J; Tang G; Tian Y; Su S; Li Y
    Oncol Lett; 2021 Apr; 21(4):279. PubMed ID: 33732355
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical Trials of Immune Checkpoint Inhibitors in Hepatocellular Carcinoma.
    Dyhl-Polk A; Mikkelsen MK; Ladekarl M; Nielsen DL
    J Clin Med; 2021 Jun; 10(12):. PubMed ID: 34208788
    [No Abstract]   [Full Text] [Related]  

  • 38. Systemic Treatment Options in Hepatocellular Carcinoma.
    Rimassa L; Pressiani T; Merle P
    Liver Cancer; 2019 Nov; 8(6):427-446. PubMed ID: 31799201
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Positioning of a molecular-targeted agent, sorafenib, in the treatment algorithm for hepatocellular carcinoma and implication of many complete remission cases in Japan.
    Kudo M; Ueshima K
    Oncology; 2010 Jul; 78 Suppl 1():154-66. PubMed ID: 20616599
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 34.